^
    over1year
    A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor (clinicaltrials.gov)
    P1, N=0, Withdrawn, Shanghai Henlius Biotech | N=30 --> 0 | Trial completion date: Mar 2024 --> Jan 2023 | Recruiting --> Withdrawn | Trial primary completion date: May 2023 --> Jan 2023
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date • Metastases
    |
    CD68 (CD68 Molecule)
    |
    HLX23
    over1year
    A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor (clinicaltrials.gov)
    P1, N=30, Recruiting, Shanghai Henlius Biotech | Not yet recruiting --> Recruiting | Trial completion date: Nov 2023 --> Mar 2024 | Trial primary completion date: Jul 2022 --> May 2023
    Enrollment open • Trial completion date • Trial primary completion date • Metastases
    |
    CD68 (CD68 Molecule)
    |
    HLX23
    3years
    A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Shanghai Henlius Biotech
    Clinical • New P1 trial
    |
    CD73 (5'-Nucleotidase Ecto)
    |
    HLX23